Abstract:Background: Dendritic, antigen-presenting cells (DCs) determine not only whether lymphocytes produce different types of immune response but also tissue-homing profiles of lymphocytes they stimulate. For example, in health, mucosal DC stimulate T cells focused to home to the mucosa; DC/T-cell circuitry thus targets immune responses to specific tissue locations. Therapies being introduced for inflammatory bowel disease (IBD) include antibodies to gut-homing molecules such as α4β7 (Vedolizumab) used ostensibly to block gut-homing lymphocytes. However, such lymphocytes are dependent on the tissue specificity of DC that stimulated them. Key messages: In health, blood DCs have the potential to home to multiple tissues including gut (α4β7+) and skin (CLA+). DCs have become gut-specific within the intestinal microenvironment stimulated partially by local retinoid to express α4β7 (mucosal homing marker) and/or CCR9 (ileal homing marker) in the absence of skin-specific indicators. They spread veiled extensions, sample their environment, acquire/process antigens, produce cytokines and initiate innate immunity. Myeloid DC also traffic to draining lymph nodes where compartmentalization of adaptive immune responses is determined by DCs from the site of antigen exposure which dictate the homing profiles of lymphocytes they stimulate. In IBD, site and activity of disease are reflected in changes in homing/activation of gut DCs and T-cells they stimulate and also, in greater gut specificity and activation of blood DC. Homing potential of DC can be modulated toward mucosa or skin by vitamins A and D, respectively. Infliximab or interleukin-6 can divert homing profiles toward skin, perhaps predisposing to skin involvement in IBD. Probiotic bacteria or their products can also change homing profiles of gut DC toward skin homing and away from gut. Conclusions: In conclusion, development of gut focused inflammation and its treatment relies on changes in DC tissue specificity; therefore, removal or diversion of gut-homing DC as well as T-cells is likely to be critical in prevention of gut-focused inflammation in IBD.

Intestinal Dendritic Cells Survey Circulatory Antigens Prior to Induction of Regulatory CD8α/β T Cells (106.2)

Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation

Dendritic cell functions in the inductive and effector sites of intestinal immunity

Small Intestinal Cd103(+) Dendritic Cells Display Unique Functional Properties That Are Conserved Between Mice and Humans

CD8αα TCRαβ Intraepithelial Lymphocytes in the Mouse Gut

Network of dendritic cells within the muscular layer of the mouse intestine

CD1d-mediated lipid presentation by CD11c+ cells regulates intestinal homeostasis

CD1d-restricted T cell pathways at the epithelial-lymphocyte-luminal interface

Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men

Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1⁺ macrophages to CD103⁺ dendritic cells

Epithelial colonization by gut dendritic cells promotes their functional diversification

Migrating Type 2 Dendritic Cells Prime Mucosal Th17 Cells Specific to Small Intestinal Commensal Bacteria

Intestinal macrophages and DCs close the gap on tolerance

Dendritic Cell-T-Cell Circuitry in Health and Changes in Inflammatory Bowel Disease and Its Treatment

A Subset of CCL25-Induced Gut-Homing T Cells Affects Intestinal Immunity to Infection and Cancer

Immune microniches shape intestinal T reg function

Immunoregulation by antigen-presenting cells in human intestinal lamina propria

Cdx2 regulates immune cell infiltration in the intestine

Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease

Development and function of natural TCR+ CD8αα+ intraepithelial lymphocytes

Pathways and mechanisms of CD4+CD8αα+ intraepithelial T cell development